{"title":"Managing heart failure with reduced ejection fraction (HFrEF): Integrating SGLT2 inhibitors.","authors":"K Melissa Hayes, Nicole Dellise","doi":"10.1097/01.NPR.0000000000000352","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Pharmacologic treatment of heart failure with reduced ejection fraction (HFrEF) has been a focus of research for decades. HFrEF guidelines recommend use of medications from four different classes (beta blockers, renin-angiotensin-aldosterone system [RAAS] inhibitors, mineralocorticoid receptor antagonists [MRAs], and sodium-glucose cotransporter-2 [SGLT2] inhibitors) to modulate the neurohormonal complexities of cardiomyopathies that result in a reduction in left ventricular function. Clinicians have become comfortable managing the triad of beta blockers, RAAS inhibitors, and MRAs. Adding the fourth class, SGLT2 inhibitors, poses more challenges, especially with regard to volume management. This article will explore clinical considerations of the integration of SGLT2 inhibitors into complex regimens in the outpatient setting.</p>","PeriodicalId":51812,"journal":{"name":"NURSE PRACTITIONER","volume":"50 9","pages":"30-35"},"PeriodicalIF":0.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NURSE PRACTITIONER","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.NPR.0000000000000352","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"NURSING","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract: Pharmacologic treatment of heart failure with reduced ejection fraction (HFrEF) has been a focus of research for decades. HFrEF guidelines recommend use of medications from four different classes (beta blockers, renin-angiotensin-aldosterone system [RAAS] inhibitors, mineralocorticoid receptor antagonists [MRAs], and sodium-glucose cotransporter-2 [SGLT2] inhibitors) to modulate the neurohormonal complexities of cardiomyopathies that result in a reduction in left ventricular function. Clinicians have become comfortable managing the triad of beta blockers, RAAS inhibitors, and MRAs. Adding the fourth class, SGLT2 inhibitors, poses more challenges, especially with regard to volume management. This article will explore clinical considerations of the integration of SGLT2 inhibitors into complex regimens in the outpatient setting.
期刊介绍：
With a circulation of 20,000, The Nurse Practitioner is the leading monthly source for clinical, practical, cutting-edge information for advanced practice nurses and other primary care clinicians. Each issue presents peer-reviewed articles that range from clinical topics and research to political and practice issues. In addition, The Nurse Practitioner provides regular features, columns, continuing education, staff development education, and more.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
